↑«PubMed-kjelde for mus:». National Center for Biotechnology Information, U.S. National Library of Medicine.
↑ 5,05,1Superti-Furga A, Rocchi M, Schafer BW, Gitzelmann R (Oct 1993). «Complementary DNA sequence and chromosomal mapping of a human proteoglycan-binding cell-adhesion protein (dermatopontin)». Genomics17 (2): 463–7. PMID8104875. doi:10.1006/geno.1993.1348.
Pochampally RR, Ylostalo J, Penfornis P, et al. (2007). «Histamine receptor H1 and dermatopontin: new downstream targets of the vitamin D receptor.». J. Bone Miner. Res.22 (9): 1338–49. PMID17547532. doi:10.1359/jbmr.070605.
Gregory SG, Barlow KF, McLay KE, et al. (2006). «The DNA sequence and biological annotation of human chromosome 1.». Nature441 (7091): 315–21. PMID16710414. doi:10.1038/nature04727.
Shaheduzzaman S, Krishnan V, Petrovic A, et al. (2002). «Effects of HIV-1 Nef on cellular gene expression profiles.». J. Biomed. Sci.9 (1): 82–96. PMID11810028. doi:10.1007/BF02256581.
Kuroda K, Okamoto O, Shinkai H (1999). «Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen.». J. Invest. Dermatol.112 (5): 706–10. PMID10233760. doi:10.1046/j.1523-1747.1999.00563.x.
Forbes EG, Cronshaw AD, MacBeath JR, Hulmes DJ (1994). «Tyrosine-rich acidic matrix protein (TRAMP) is a tyrosine-sulphated and widely distributed protein of the extracellular matrix.». FEBS Lett.351 (3): 433–6. PMID8082810. doi:10.1016/0014-5793(94)00907-4.